Rossari Biotech Limited Q4 and FY24 Earnings Conference Call Transcript April 30, 2024
-
We are pleased to report another strong quarter for the company, driven by healthy Y-o-Y growth in both revenues and profits. This performance was largely driven by the expansion of our HPPC business.
-
While challenges in our TSC and AHN divisions persisted due to external industry headwinds, we remain optimistic about the recovery of these segments in the upcoming fiscal.
-
We are particularly focused on specialty surfactants, phenoxy series, institutional cleaning, and performance chemicals.
-
Our recent expansion plan at Dahej along with increased its ethoxylation capacity, will allow us to meet growing demand in these key segments.
-
We expanded our customer base for key HPPC products, leading to a robust 18% growth in this division.
-
Our Institutional Cleaning segment has achieved exceptional results during the year, serving major sectors such as airports, railways, hotels, and healthcare that rely on specialized cleaning solutions.
-
We take pride in our growth from an Rs. 700 crore top line to our expected milestone of around Rs. 2,000 crore top line in FY25.
Subscribe To Our Free Newsletter |